Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population
- PMID: 26656145
- DOI: 10.1016/j.jchf.2015.08.006
Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population
Abstract
Objectives: This study sough to test whether elevated lipoprotein(a) levels and corresponding LPA risk genotypes (low number of kringle IV type 2 repeats, rs3798220 and rs10455872, minor allele carriers) are associated with an increased risk of heart failure (HF).
Background: Elevated lipoprotein(a) levels represent a genetically determined risk factor for myocardial infarction (MI) and aortic valve stenosis (AVS). It is presently unknown whether elevated lipoprotein(a) levels also cause heart failure (HF).
Methods: We combined 2 general population studies, the Copenhagen City Heart Study (n = 10,855) and the Copenhagen General Population Study (n = 87,242), which totaled 98,097 Danish participants, of whom 4,122 were diagnosed with HF (1976 to 2013). We conducted observational and genetic instrumental variable analyses in a Mendelian randomization study design, assessing evidence of causality, and we performed mediation analyses.
Results: Elevated lipoprotein(a) levels were associated with multivariable adjusted hazard ratios for HF of 1.10 (95% CI: 0.97 to 1.25) for the 34th to 66th percentiles (8 to 19 mg/dl), 1.24 (95% CI: 1.08 to 1.42) for the 67th to 90th percentiles (20 to 67 mg/dl), 1.57 (95% CI: 1.32 to 1.87) for the 91st to 99th percentiles (68 to 153 mg/dl), and 1.79 (95% CI: 1.18 to 2.73) for levels >99th percentile (>153 mg/dl) versus levels <34th percentile (<8 mg/dl) (trend, p < 0.001), corresponding to a population-attributable risk of 9%. By combining all LPA risk genotypes, instrumental variable analysis yielded a genetic relative risk for HF of 1.18 (95% CI: 1.04 to 1.34) per 10-fold higher lipoprotein(a) levels, which was comparable to the corresponding observational hazard ratio of 1.22 (95% CI: 1.11 to 1.35). Upon exclusion of participants diagnosed with MI or AVS, risk estimates were attenuated. Accordingly, 63% (95% CI: 45% to 99%) of HF risk was mediated via MI and AVS combined.
Conclusions: Elevated lipoprotein(a) levels and corresponding LPA risk genotypes were associated with an increased risk of HF consistent with a causal association. The association appeared to be partly mediated by MI and AVS.
Keywords: genetics; heart failure; lipoproteins.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Lipoprotein(a) and Heart Failure: Another Reason to Study Interventions in Patients With Very High Levels of Lipoprotein(a)?JACC Heart Fail. 2016 Jan;4(1):88-9. doi: 10.1016/j.jchf.2015.11.001. JACC Heart Fail. 2016. PMID: 26738954 No abstract available.
Similar articles
-
Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.J Am Coll Cardiol. 2014 Feb 11;63(5):470-7. doi: 10.1016/j.jacc.2013.09.038. Epub 2013 Oct 23. J Am Coll Cardiol. 2014. PMID: 24161338 Clinical Trial.
-
Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population.J Clin Endocrinol Metab. 2015 Jul;100(7):2690-9. doi: 10.1210/jc.2015-1096. Epub 2015 May 4. J Clin Endocrinol Metab. 2015. PMID: 25938632
-
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.JAMA. 2009 Jun 10;301(22):2331-9. doi: 10.1001/jama.2009.801. JAMA. 2009. PMID: 19509380
-
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.J Lipid Res. 2016 Nov;57(11):1953-1975. doi: 10.1194/jlr.R071233. Epub 2016 Sep 27. J Lipid Res. 2016. PMID: 27677946 Free PMC article. Review.
-
Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?Curr Opin Lipidol. 2020 Jun;31(3):125-131. doi: 10.1097/MOL.0000000000000681. Curr Opin Lipidol. 2020. PMID: 32304380 Review.
Cited by
-
Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases.Pharmaceuticals (Basel). 2023 Jun 23;16(7):919. doi: 10.3390/ph16070919. Pharmaceuticals (Basel). 2023. PMID: 37513831 Free PMC article. Review.
-
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society.Eur Heart J. 2023 Oct 14;44(39):4157-4173. doi: 10.1093/eurheartj/ehad472. Eur Heart J. 2023. PMID: 37611089 Free PMC article.
-
Low LPA gene kringle IV-2 repeat copy number association with elevated lipoprotein (a) concentration as an independent risk factor of coronary atherosclerotic heart disease in the Chinese Han population.Lipids Health Dis. 2018 May 10;17(1):111. doi: 10.1186/s12944-018-0753-1. Lipids Health Dis. 2018. PMID: 29747697 Free PMC article.
-
Lipoprotein(a): Role in atherosclerosis and new treatment options.Biomol Biomed. 2023 Jul 3;23(4):575-583. doi: 10.17305/bb.2023.8992. Biomol Biomed. 2023. PMID: 37183706 Free PMC article. Review.
-
Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals.Genome Med. 2020 Aug 21;12(1):74. doi: 10.1186/s13073-020-00771-0. Genome Med. 2020. PMID: 32825847 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous